Enalapril Maleate Oral Solution (strength: 150ml:0.15g, licensed by Chengdu Easton Biopharmaceutical Co., LTD.), manufactured in by Huayi Pharmaceutical (Anhui) Co., LTD., has been successfully approved for marketing!
Subiyi® Enalapril Maleate Oral Solution is an inhibitor of angiotensin-converting enzyme (ACE), a peptidyl dipeptidase that converts angiotensin I to the pressor substance angiotensin II. Enalapril is absorbed in vivo and hydrolyzed to enalaprilat, which inhibits ACE, leads to a decrease in the plasma concentration of angiotensin II, an increase in plasma renin activity (the negative feedback mechanism of renin release is weakened), and a decrease in aldosterone secretion. Enalapril reduces blood pressure mainly by inhibiting renin-angiotensin-aldosterone system, which plays an important role in blood pressure regulation.
With many years of rich experience in project management and superb technical strength, Huayi has won the trust of customers. Huayi and Easton Biopharma cooperate because of the common initial intention and achieve win-win because of deep mutual trust, boosting the product successfully approved by NMPA! Look forward to more exciting cooperation between the two sides in the future.
Adhering to professional, concentrated and dedicated service concept and relying on excellent professional and consistent technology, Huayi Pharma will continue to provide cost-effective and reliable services in terms of drug research and development technology and commercialized production for the drug research and development and production enterprises, and to promote the development of the pharmaceutical industry!